10-Q: Regen Biopharma Faces Critical Going Concern Doubts Amidst Widening Losses and Near-Zero Cash Reserves

Regen Biopharma, an early-stage biopharmaceutical company, reported a significantly increased net loss and critically low cash balance for the six months ended March 31, 2025, leading to substantial doubt about its ability to continue as a going concern.

Summary

• Regen Biopharma, Inc. (RGBP) reported a net loss of $(534,739) for the six months ended March 31, 2025, a significant increase from $(267,387) in the prior year, primarily due to a derivative loss of $(287,053).
• The company's cash balance stood at a critically low $1,761 as of March 31, 2025, down from $78,114 at March 31, 2024.
• Total liabilities increased to $5,867,880 as of March 31, 2025, from $5,378,456 at September 30, 2024, contributing to a worsening working capital deficit of $(5,716,131).
• Revenue remained flat at $118,130 for the six months ended March 31, 2025, derived from license agreements with related party Zander Therapeutics, Inc. and Oncology Pharma, Inc.
• Research and Development (R&D) expenses were $0 for the six months ended March 31, 2025, a sharp decrease from $87,661 in the comparable prior period, indicating a halt in core development activities.
• The company's accumulated deficit reached approximately $21 million as of March 31, 2025.
• Management explicitly stated that there is "substantial doubt about the Company's ability to continue as a going concern" without additional funding.
• Disclosure controls and procedures were deemed ineffective by the company's Principal Executive Officer and Principal Financial Officer.

Sentiment

Score: 1

Explanation: The company faces severe liquidity issues, a widening net loss driven by non-operating factors, a complete halt in R&D spending, and explicit going concern doubts, indicating a highly distressed financial position with a high probability of failure or significant further dilution.

Positives

• Net cash used in operating activities decreased to $(167,609) for the six months ended March 31, 2025, compared to $(371,658) in the prior year, indicating a reduced operational cash burn.
• Operating loss decreased to $(174,727) for the six months ended March 31, 2025, from $(223,853) in the prior year, primarily due to a reduction in overall operating expenses, excluding rent.

Negatives

• The net loss significantly widened to $(534,739) for the six months ended March 31, 2025, largely due to a substantial derivative loss.
• The company's cash balance is critically low at $1,761, raising severe liquidity concerns.
• The working capital deficit increased by $481,026 to $(5,716,131), primarily due to an increase in derivative liability.
• Research and Development (R&D) expenses were $0 for the six months ended March 31, 2025, which is highly concerning for an early-stage biopharma company.
• Management has expressed "substantial doubt about the Company's ability to continue as a going concern" without securing additional funding.
• Disclosure controls and procedures were evaluated as ineffective by the company's management.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to recurring losses, negative operating cash flows, and dependence on additional funding.
• The company is in the early stages of product development and requires FDA approval to market any products, with no assurance of obtaining such approval.
• There is no assurance that the company will be able to sell or license any products on favorable terms, if at all.
• Financial statements rely on estimates and assumptions, and actual results could differ materially.
• The fair value of embedded derivatives, valued using the Black-Scholes model, can fluctuate significantly, impacting financial results.
• The company holds investments in privately held equity securities (Zander Therapeutics, Inc.) for which no public market exists, making their valuation subjective and illiquid.
• Related party transactions, including loans and license agreements, may present conflicts of interest and impact financial stability.

Future Outlook

The company expects to continue incurring significant professional costs to remain publicly traded and substantial research and development costs for product development. It is highly dependent on securing additional working capital funding through equity and/or debt to continue operations and execute its business plans.

Management Comments

• "The Company has incurred and expects to continue to incur significant professional costs to remain as a publicly traded company and it has incurred and expects to continue incur significant research & development cost for products development."
• "Without additional funding, there is substantial doubt about the Company’s ability to continue as a going concern for the twelve months from the date of these financial statements."
• David Koos, Principal Executive Officer and Principal Financial Officer, concluded that the company's disclosure controls and procedures were ineffective as of March 31, 2025.

Industry Context

Regen Biopharma operates in the highly capital-intensive and high-risk biopharmaceutical sector, focusing on early-stage regenerative medical applications for oncology and autoimmune diseases. The industry typically demands substantial and sustained investment in R&D, long development cycles, and successful clinical trials to achieve commercialization. Regen Biopharma's current financial state, characterized by minimal cash, a large accumulated deficit, and a complete cessation of R&D spending in the last six months, starkly contrasts with the typical operational requirements and investment profiles of even small, clinical-stage biopharma companies. Its revenue model, primarily based on license agreements with related parties and one unrelated entity rather than product sales, underscores its very early and financially precarious position within the industry.

Comparison to Industry Standards

• **R&D Spending:** Regen Biopharma reported $0 in R&D expenses for the six months ended March 31, 2025. This is drastically below industry norms for a biopharma company in the 'early stages of development' aiming for Phase I/II clinical trials. For context, small-cap biotechs typically spend millions to tens of millions per quarter on R&D to advance their pipelines, while larger players invest billions. The absence of R&D spending suggests a halt in active product development, which is critical for growth in this sector.
• **Cash Position:** With only $1,761 in cash, Regen Biopharma's liquidity is critically low. This is far below the cash reserves typically maintained by biopharma companies, which often hold enough cash to fund operations for at least 12-24 months, especially those in clinical development, to cover high R&D and operational burn rates. A healthy small-cap biotech might aim for $50M-$100M+ in cash.
• **Going Concern:** The explicit statement of 'substantial doubt about the Company's ability to continue as a going concern' is a severe red flag, indicating a distressed financial state that is not typical for a progressing biopharma firm.
• **Revenue Model:** The company's revenue primarily stems from license agreements, including those with related parties, rather than commercial product sales. While common for pre-commercial biopharma, the flat and minimal revenue ($118,130 for six months) indicates limited commercial progress or significant licensing deals compared to industry peers with active pipelines.

Corporate Governance

Related Party Transactions

• Accounts receivable from Zander Therapeutics, Inc. (under common control) amounted to $149,723 as of March 31, 2025.
• Investment securities in Zander Therapeutics, Inc. (7.9% ownership) were valued at $17,733 as of March 31, 2025.
• Revenue from Zander Therapeutics, Inc. was $54,850 for the six months ended March 31, 2025, related to an anniversary expense receivable from a license agreement.
• Notes payable to related parties totaled $210,363 as of March 31, 2025, including $63,948 from David Koos (sole officer/director), $87,215 from BST Partners (controlled by David Koos), and $59,200 from Zander Therapeutics, Inc.
• The company has a sublease agreement with BST Partners for office space at $5,000 per month plus shared expenses reimbursement.

Stakeholder Impact

• **Shareholders:** Face significant dilution risk from potential future equity raises, continued erosion of value due to ongoing losses, and high uncertainty regarding the company's long-term viability given the explicit going concern warning.
• **Employees:** High job insecurity due to the company's precarious financial position and minimal cash reserves.
• **Creditors:** Increased risk of default on outstanding notes payable and convertible notes due to the company's severe liquidity issues and accumulated deficit.
• **Licensees (e.g., Oncology Pharma, Zander Therapeutics):** Potential disruption or termination of existing license agreements if the company is unable to continue operations.

Next Steps

• Obtain additional working capital funding from the sale of equity and/or debt securities to continue operations and execute development plans.
• Address and remediate the identified ineffectiveness of disclosure controls and procedures.

Key Dates

Recommendation

Keywords

Biopharma, Regenerative Medicine, Oncology, Autoimmune Disease, SEC Filing, 10-Q, Going Concern, Derivative Liability, Research and Development, Clinical Trials, FDA Approval, Preferred Stock, Convertible Notes, Liquidity, Working Capital Deficit